IVADANTIN
LOE Approachingnitrofurantoin sodium
NDAINJECTIONINJECTABLE
Approved
Sep 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IVADANTIN (nitrofurantoin sodium) is an injectable nitrofuran antibiotic approved in 1960 for urinary tract infections and related bacterial conditions. It works by inhibiting bacterial enzyme systems essential for DNA synthesis. The product represents a legacy small-molecule antibiotic with limited modern clinical use.
LOE Approaching
Minimal commercial activity with approaching LOE suggests limited team expansion and focus on market defense rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
IVADANTIN offers minimal career growth potential with zero linked job openings and approaching loss of exclusivity. Career positions on this product are typically cost-containment focused and found in legacy product management, manufacturing, or supply chain teams.
Supply Chain ManagerManufacturing Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.